Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs Vanguard S&P 500 ETF (VOO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spyre Therapeutics Inc. Common Stock vs Vanguard S&P 500 ETF — how do they compare? Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B), while Vanguard S&P 500 ETF trades at $704.96 (market cap $1.80T). The key difference: Vanguard S&P 500 ETF is far larger — about 239.4× Spyre Therapeutics Inc. Common Stock's market cap, and Vanguard S&P 500 ETF is trading nearer its 52-week high, Spyre Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Spyre Therapeutics Inc. Common Stock for 0 Days and Vanguard S&P 500 ETF for 57 Days on average.
| SYRE | VOO | |
|---|---|---|
Market Cap | $7.52B | $1.80T |
Volume | 1,441,031 | 4,954,490 |
Sector | Health | Broad Market / Factor |
52-Week High | $108.92 | $716.17 |
52-Week Low | $22.18 | $580.93 |
Typical Hold Time | 0 Days | 57 Days |
Enterprise Value | $6.52B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
VOO trades at $715.14 with minimal daily movement, showing strong technical momentum with bullish moving averages. The ETF maintains its position as a core S&P 500 holding with upcoming dividend distribution. Recent news highlights its role in long-term wealth building and recession resilience, though short interest increased 46.9% in September.
VOO offers diversified exposure to large-cap US equities with low expense ratio advantages. Key risks include market-wide volatility and potential earnings growth slowdown from 35% to 15% in 2027. The ETF remains a foundational holding for long-term investors despite near-term valuation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →About Vanguard S&P 500 ETF
VOO is a foundational ETF that tracks the S&P 500 Index, providing exposure to 500 of the largest and most established companies in the United States. Renowned for its ultra-low expense ratio and tax efficiency, it serves as a core building block for long-term investors seeking to capture the total return of the U.S. large-cap market in a single, highly liquid vehicle.
Read more on VOO →
